Jaguar Health 将来の成長

Future 基準チェック /26

Jaguar Healthは、25.6%と41.8%でそれぞれ年率25.6%で利益と収益が成長すると予測される一方、EPSはgrowで147.4%年率。

主要情報

25.6%

収益成長率

147.4%

EPS成長率

Pharmaceuticals 収益成長	17.9%
収益成長率	41.8%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	19 Jul 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:1JA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	19	-24	N/A	-12	1
12/31/2024	13	-30	N/A	-20	1
6/30/2024	10	-36	-29	-29	N/A
3/31/2024	10	-38	-30	-30	N/A
12/31/2023	10	-41	-33	-33	N/A
9/30/2023	11	-40	-33	-32	N/A
6/30/2023	11	-44	-34	-34	N/A
3/31/2023	11	-42	-37	-35	N/A
12/31/2022	12	-47	-35	-33	N/A
9/30/2022	11	-54	-37	-36	N/A
6/30/2022	8	-54	-38	-37	N/A
3/31/2022	6	-59	-36	-36	N/A
12/31/2021	4	-53	-35	-35	N/A
9/30/2021	5	-50	-30	-30	N/A
6/30/2021	7	-46	-24	-24	N/A
3/31/2021	10	-42	-18	-18	N/A
12/31/2020	9	-39	-15	-15	N/A
9/30/2020	8	-35	-14	-14	N/A
6/30/2020	7	-39	-20	-20	N/A
3/31/2020	5	-45	-21	-21	N/A
12/31/2019	6	-45	-20	-20	N/A
9/30/2019	6	-48	-22	-22	N/A
6/30/2019	6	-43	-16	-16	N/A
3/31/2019	5	-34	-17	-17	N/A
12/31/2018	4	-32	-23	-23	N/A
9/30/2018	4	-41	-23	-23	N/A
6/30/2018	4	-30	-23	-23	N/A
3/31/2018	4	-24	N/A	-19	N/A
12/31/2017	4	-22	N/A	-10	N/A
9/30/2017	3	-5	N/A	-7	N/A
6/30/2017	2	-14	N/A	-17	N/A
3/31/2017	1	-17	N/A	-15	N/A
12/31/2016	0	-15	N/A	-14	N/A
12/31/2015	0	5	N/A	1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 1JA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 1JA今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 1JA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 1JAの収益 ( 41.8% ) German市場 ( 5.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: 1JAの収益 ( 41.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 1JAの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Jaguar Health 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care At American Society for Radiation Oncology Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024

Jaguar Health, Inc. Announces Issuance of New Hong Kong Patent Bolsters Ip Protection for Jaguar Health in the Treatment of Short Bowel Syndrome

Jaguar Health, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Napo Pharmaceuticals Announces Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders

Jaguar Health, Inc. Reports Phase 3 Ontarget Trial Results for Its Cancer Supportive Care Drug Crofelemer

Jaguar Health Announces 1-For-60 Reverse Stock Split in Order to Support Compliance with Nasdaq's Listing Standards

First quarter 2024 earnings released: US$0.058 loss per share (vs US$2.39 loss in 1Q 2023)

Jaguar Health, Inc., Annual General Meeting, Jun 21, 2024

Jaguar Health, Inc. to Report Q1, 2024 Results on May 14, 2024

Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration

Jaguar Health Receives Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement

Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International

Full year 2023 earnings released: US$1.79 loss per share (vs US$36.18 loss in FY 2022)

Jaguar Health, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Jaguar Health Receives Notification Letter from The Nasdaq Stock Market LLC

Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health, Inc. announced that it has received $0.06 million in funding

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.38 loss per share (vs US$8.83 loss in 3Q 2022)

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New major risk - Financial position

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$8.82 loss in 2Q 2022)

Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome

Napo Pharmaceuticals Submits Investigational New Drug Application to FDA for MicroVillus Inclusion Disease

New major risk - Market cap size

Jaguar Health, Inc., Annual General Meeting, Jul 07, 2023

Jaguar Health, Inc. Appoints Stacey Tinianov to Scientific Advisory Board

First quarter 2023 earnings released: US$2.39 loss per share (vs US$30.17 loss in 1Q 2022)

Jaguar Health Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Jaguar Health, Inc. to Report Q1, 2023 Results on May 15, 2023

Jaguar Health, Inc. announced that it has received $1.86 million in funding

Jaguar Health, Inc. announced that it expects to receive $1.86 million in funding

Full year 2022 earnings released

Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement

Jaguar Health, Inc. Provides Updates Regarding its Focus on Rare and Orphan Disease Indications in the U.S. & Europe

Jaguar Health, Inc. and Napo Pharmaceuticals Appoints Sandra M. Swain to the Scientific Advisory Board

Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (Cid) in Breast Cancer Patients

European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. announced delayed 10-Q filing

Jaguar Health, Inc. Appoints Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee

Jaguar Health, Inc. Announces Appointment of Pravin Chaturvedi as Chief Scientific Officer and Chair of the Scientific Advisory Board

Jaguar Health Regains Compliance with Nasdaq Bid Price Requirement

Jaguar Health Explores Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler’ Covid-19 Recovery Patients in Europe

Jaguar Health Got Letter from Nasdaq Staying Stipulation for Company to Comply with Minimum Bid Price Requirement by Dec. 23

New 90-day high: €0.40

Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. Plan to Study, Develop and Commercialize Crofelemer, the Company’s Novel Proprietary Drug, for an Indication of Inflammatory Diarrhea, Initially in Europe

Revenue misses expectations

Third quarter 2020 earnings released: US$0.20 loss per share

Jaguar Health Receives Positive Nasdaq Listing Determination

New 90-day low: €0.24

Jaguar Health, Inc. Announces Appointment of Melissa Yeager, J.D. as Senior Vice President, Regulatory Affairs and Quality Assurance

New 90-day low: €0.26

New 90-day low - €0.34

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘